Satoi Sohei, Yanagimoto Hiroaki, Yamamoto Tomohisa, Toyokawa Hideyoshi, Hirooka Satoshi, Yamaki So, Opendro Singh Sapam, Inoue Kentaro, Michiura Taku, Ryota Hironori, Matsui Yoichi, Kon Masanori
Department of Surgery, Kansai Medical University, 2-5-1, Shin-machi, Hirakata-City, Osaka, 573-1010, Japan.
World J Surg Oncol. 2016 Jan 20;14(1):14. doi: 10.1186/s12957-016-0767-y.
The aim of current study is to verify usefulness of staging laparoscopy (stag-lap) for patient's selection and to find prognostic factors in patients with radiographically defined locally advanced (RD-LA) pancreatic ductal adenocarcinoma (PDAC).
The LA disease was defined as an unresectable disease without distant organ metastasis based on resectability status of NCCN guideline in this study. Stag-lap was performed in 67 patients with RD-LA (2007-2012) which were divided into 4 groups according to metastatic site: group CY (peritoneal fluid or washing cytology positive and without any distant organ metastasis); group P (peritoneal dissemination); group L (liver metastasis); group LA (peritoneal fluid or washing cytology negative and without any distant organ metastasis). Clinical backgrounds, survival curves, and prognostic factors were investigated.
There were 16 patients in CY group (24%), 13 patients in P group (19%), 10 patients in L group (15%), and 28 patients in LA group (42%). Median survival time was 13 months in CY group and 11 months in LA group, which was significantly better than 7 months in P group, respectively (p<0.05). The rate of emergence of ascites in LA was significantly better than in CY or P groups (p<0.05). Multivariate analysis showed that the presence of partial response and administration of second-line chemotherapy were significantly independent prognostic factors.
The majority of PDAC patients with RD-LA had occult distant organ metastasis. Clinical features and survival curves were different depending on the site of occult distant organ metastasis. Administration of second-line chemotherapy and responsiveness to chemotherapy were associated with favorable prognosis. Staging laparoscopy should be routinely performed in patients with RD-LA PDAC (UMIN000019936).
本研究的目的是验证分期腹腔镜检查(stag-lap)对患者选择的有用性,并找出影像学定义的局部晚期(RD-LA)胰腺导管腺癌(PDAC)患者的预后因素。
在本研究中,根据NCCN指南的可切除性状态,LA疾病被定义为无远处器官转移的不可切除疾病。对67例RD-LA患者(2007 - 2012年)进行分期腹腔镜检查,根据转移部位分为4组:CY组(腹水或冲洗液细胞学阳性且无任何远处器官转移);P组(腹膜播散);L组(肝转移);LA组(腹水或冲洗液细胞学阴性且无任何远处器官转移)。研究临床背景、生存曲线和预后因素。
CY组有16例患者(24%),P组有13例患者(19%),L组有10例患者(15%),LA组有28例患者(42%)。CY组的中位生存时间为13个月,LA组为11个月,均显著优于P组的7个月(p<0.05)。LA组腹水出现率明显优于CY组或P组(p<0.05)。多因素分析显示,部分缓解的存在和二线化疗的应用是显著的独立预后因素。
大多数RD-LA的PDAC患者存在隐匿性远处器官转移。根据隐匿性远处器官转移的部位,临床特征和生存曲线有所不同。二线化疗的应用和对化疗的反应与良好预后相关。对于RD-LA PDAC患者应常规进行分期腹腔镜检查(UMIN000019936)。